Form 4/A for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2021-12-07 00:00:00 ET · period of report 2021-08-31 · accession 0001213900-21-063944 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2021-12-07 | 2021-08-31 | ORMP | KIDRON NADAV | Pres, CEO, Dir | A - Grant | — | +100.0K | 838.2K | +14% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-31 | A | A | 100,000 | — | 838,209 | D | — | — | (F1) Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis. (F2) This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 748,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 838,209 shares of common stock following the reported transaction. |